Sarilumab

Interleukin-6 Receptor Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Sarilumab is a drug in the Interleukin-6 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Interleukin 6 Receptor Antagonists. DrugCentral lists 1 molecular target, including IL6R. Recorded indications include Rheumatoid arthritis.

• Drug class: Interleukin-6 Receptor Antagonist.
• Mechanism of action: Interleukin 6 Receptor Antagonists.
• Molecular targets: IL6R (1 listed in DrugCentral).
• Indications: Rheumatoid arthritis.
• ATC code: L04AC14 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Rheumatoid arthritis

Contraindications (1)

• Bacterial infectious disease

Mechanism & targets

• Mechanism of action (MoA): Interleukin 6 Receptor Antagonists
• Established pharmacologic class: Interleukin-6 Receptor Antagonist

Molecular targets (1)

Target	Gene	Action	Activity
Interleukin-6 receptor subunit alpha	IL6R	other	Kd 11.10

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2017-09-27	PMDA	—	SANOFI KK
2017-06-23	EMA	—	sanofi-aventis groupe
2017-05-22	FDA	—	SANOFI SYNTHELABO

ATC classification

ATC code	Therapeutic hierarchy
L04AC14	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Joint swelling	2484.4
Anti-cyclic citrullinated peptide antibody positive	2048.2
Pericarditis	1844.6
Hand deformity	1749.8
Pemphigus	1689.8
Rheumatoid factor positive	1607.9
Glossodynia	1586.4
Systemic lupus erythematosus	1533.8
Wound	1516.5
Duodenal ulcer perforation	1475.0
Hepatic enzyme increased	1451.2
Synovitis	1449.6

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 1189541-98-7
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sarilumab used for?

DrugCentral lists the following indications for Sarilumab: Rheumatoid arthritis.

How does Sarilumab work?

Sarilumab is classified as Interleukin 6 Receptor Antagonists; its molecular targets in DrugCentral include IL6R.

When was Sarilumab first approved?

Sarilumab was first approved by the FDA in 2017.

What drug class does Sarilumab belong to?

Sarilumab is in the Interleukin-6 Receptor Antagonist class.

Sources

• DrugCentral drug card 5237 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2108730 — compound record and bioactivity
• DrugBank DB11767 — drug record
• FDA UNII NU90V55F8I — substance identity
• DailyMed: FDA labels for Sarilumab — current prescribing information (label search)
• UniProt P08887 (IL6R) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.